Introduction: The currently available anti-HIV-1 drugs can control the infection but do not
eradicate the virus. Their long-term use can lead to side effects and resistance to therapy …

Despite immense progress in our ability to prevent and treat HIV-1 infection, HIV-1 remains
an incurable disease and a highly efficacious HIV-1 vaccine is not yet available. Additional …

Developing an effective prophylaxis HIV-1 vaccine is likely to require the elicitation of
broadly neutralizing antibodies (bnAbs). As the HIV-1 envelope (Env) glycoprotein–the sole …

Highlights•Broadly neutralizing antibodies are promising for HIV-1 prevention and
therapy.•Newly identified bNAbs reveal novel epitopes and binding modes.•Effective …

Antibodies that naturally develop in some individuals infected with human immunodeficiency
virus 1 (HIV-1) and are capable of broadly neutralizing diverse strains of HIV-1 are useful for …

Summary bNAbs may offer advantages over traditional ART for both the prevention and
treatment of HIV-1 infection. In addition, bNAbs may target the latent viral reservoir. bNAb …

A large array of broadly neutralizing antibodies (bnAbs) against HIV have been isolated and
described, particularly in the last decade. This continually expanding array of bnAbs has …

Early clinical studies support additional evaluation of bNAbs. Antibodies may offer
advantages over standard ART for HIV-1 prevention and therapy, and as components of …

Despite substantial progress in confronting the global HIV-1 epidemic since its inception in
the 1980s, better approaches for both treatment and prevention will be necessary to end the …

Vaccines that protect against viral infection usually elicit neutralizing antibodies, but HIV-1
vaccine candidates have failed to induce broad and potent such responses. Broadly active …